This Director Sold 42,000 Shares of Wave Life Sciences for $630,000. What Investors Should Know About This Biotech Company.

1 hour ago 1

Sarah Sidlow, The Motley Fool

Wed, January 14, 2026 astatine 7:38 AM CST 5 min read

Adrian Rawcliffe disposed of 42,000 shares for a full transaction worth of ~$630,000 connected Dec. 8, 2025.
This transaction was derivative-based, involving the workout and contiguous merchantability of options; each enactment was done nonstop ownership with nary indirect entities involved.
These 10 stocks could mint the adjacent question of millionaires ›

On Dec. 8, 2025, Adrian Rawcliffe, Director astatine Wave Life Sciences (NASDAQ:WVE), exercised 42,000 options and instantly sold the resulting shares successful an open-market transaction valued astatine $630,000, arsenic disclosed successful this SEC Form 4 filing.

Metric

Value

Shares sold (direct)	42,000
Transaction value	~$630,000.0
Post-transaction shares (direct)	12,700
Post-transaction worth (direct ownership)	~$235,204.0

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($15.00); post-transaction worth based connected the marketplace adjacent terms connected Dec. 8, 2025.

Was this transaction executed done nonstop oregon indirect ownership channels?
All shares progressive were straight held by Rawcliffe; determination were nary indirect holdings oregon entity transfers, and his indirect ownership remains zero arsenic of Dec. 10, 2025.
What is the derivative discourse underlying this sale?
The filing documents that each 42,000 shares sold originated from the workout of vested options, which were instantly converted and sold successful the unfastened market.

Metric

Value

Price (as of marketplace adjacent Dec. 8, 2025)	$18.52
Market capitalization	$2.64 billion
Revenue (TTM)	$109.2 million
Net income (TTM)	($121.9 million)

* 1-year show information calculated utilizing Dec. 8, 2025 arsenic the notation date.

Develops stereopure oligonucleotide therapeutics targeting uncommon familial diseases, with a objective pipeline addressing neurodegenerative, neuromuscular, hepatic, and retinal indications.
Operates a platform-based exemplary leveraging proprietary PRISM exertion to plan and optimize caller RNA-targeting medicines; gross is chiefly generated done collaborations and milestone payments from pharmaceutical partners.
Serves planetary pharmaceutical companies, probe institutions, and patients with unmet aesculapian needs successful uncommon and superior familial disorders.

Wave Life Sciences is simply a clinical-stage biotechnology institution focused connected advancing stereopure oligonucleotide therapeutics for uncommon familial diseases. The institution leverages its PRISM level and strategical partnerships to accelerate cause find and improvement crossed aggregate therapeutic areas. Its differentiated attack and collaboration-driven exemplary presumption it arsenic an innovator wrong the familial medicines sector.